It has been shown that several amphipathic helical peptide mimetics of apolipoprotein (apo) A-l inhibit atherosclerosis, improve vascular function, and reduce inflammatory processes. It has also been shown that co-administration of peptide with statin regresses already-existing atherosclerotic lesions. We hypothesize that these peptides modify high density lipoprotein (HDL) or recruit phospholipids and apo A-l to form apo Al- containing particles which in turn recruit antiatherogenic enzymes such as paraoxonase-1 (PON-1) and/or platelet activating-factor acetylhydrolase (PAF-AH). We intend to determine if peptides have antiatherosclerotic properties in the absence of apo A-l or PON-1. We hypothesize that mimetic peptides act by recruiting apo A-l into new, more bioactive particles, or by modifying the structure of apo A-l so that it is more bioactive. This may allow it to recruit and/or activate PON-1, resulting in a reduction of atherogenic oxidized lipids. We will study three peptides: 4F, which is strongly atheroprotective;3F[14], which has no observed atheroprotective properties;and peptide 2F, which is intermediate in its in vitro atheroprotective properties. These peptides differ only in the number of phenylalanine residues on the hydrophobic face. The following specific aims are proposed:
Specific Aim 1 : The role of apo A-l in peptide function. The hypothesis to be tested is that apo A-l is required for mimetic peptide function, a: We will study the effect of peptides on apo A-l synthesis and secretion, b: We will use atherosclerosis-susceptible mice, either expressing wild-type apo A-l or apo A-l null. We will study the requirement of apo A-l for peptide-mediated functions.
Specific Aim 2 : The role of PON-1 in peptide function. The hypothesis to be tested is that PON-1 is required for mimetic peptide function, a: Peptide-mediated changes in PON-1 levels and activity will be determined, b: Using atherosclerosis-susceptible mice expressing PON-1 or PON-1 null, anti-inflammatory properties of the peptides will be studied. HDL is considered to be protective against atherosclerotic heart disease. We are studying the major protein of HDL, apo A-l, using small molecules called peptides to mimic the properties of apo A-l. These studies will be done using mouse models that are susceptible to atherosclerosis. The objective is to better understand how apo A-l and HDL are protective, and to develop methods to improve those protective properties.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL034343-25
Application #
8375040
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
25
Fiscal Year
2012
Total Cost
$239,586
Indirect Cost
$74,354
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
White, C Roger; Giordano, Samantha; Anantharamaiah, G M (2016) High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms. Chem Phys Lipids 199:161-169
Namiri-Kalantari, Ryan; Gao, Feng; Chattopadhyay, Arnab et al. (2015) The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory. Biofactors 41:153-9
White, C Roger; Goldberg, Dennis I; Anantharamaiah, G M (2015) Recent developments in modulating atherogenic lipoproteins. Curr Opin Lipidol 26:369-75
Guo, Lilu; Chen, Zhongyi; Amarnath, Venkataraman et al. (2015) Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. Antioxid Redox Signal 22:1633-45
Navab, Mohamad; Chattopadhyay, Arnab; Hough, Greg et al. (2015) Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis. J Lipid Res 56:871-87
Datta, Geeta; Kramer, Philip A; Johnson, Michelle S et al. (2015) Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4F. Biochem J 467:517-27
Segrest, Jere P; Jones, Martin K; Catte, Andrea et al. (2015) A robust all-atom model for LCAT generated by homology modeling. J Lipid Res 56:620-34
Segrest, Jere P; Jones, Martin K; Catte, Andrea et al. (2015) Surface Density-Induced Pleating of a Lipid Monolayer Drives Nascent High-Density Lipoprotein Assembly. Structure 23:1214-26
Sharifov, Oleg F; Xu, Xin; Gaggar, Amit et al. (2014) L-4F inhibits lipopolysaccharide-mediated activation of primary human neutrophils. Inflammation 37:1401-12
Reddy, Srinivasa T; Navab, Mohamad; Anantharamaiah, G M et al. (2014) Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta 1841:162-7

Showing the most recent 10 out of 197 publications